PYXS
Price:
$1.9
Market Cap:
$112.90M
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for tre...[Read more]
Industry
Biotechnology
IPO Date
2021-10-08
Stock Exchange
NASDAQ
Ticker
PYXS
According to Pyxis Oncology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.79. This represents a change of -72.01% compared to the average of -6.39 of the last 4 quarters.
The mean historical PE Ratio of Pyxis Oncology, Inc. over the last ten years is -42.22. The current -1.79 PE Ratio has changed 323.96% with respect to the historical average. Over the past ten years (40 quarters), PYXS's PE Ratio was at its highest in in the December 2022 quarter at 0.51. The PE Ratio was at its lowest in in the September 2020 quarter at -22.88.
Average
-42.22
Median
-4.34
Minimum
-169.94
Maximum
-0.38
Discovering the peaks and valleys of Pyxis Oncology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 159.39%
Maximum Annual PE Ratio = -0.38
Minimum Annual Increase = -91.34%
Minimum Annual PE Ratio = -169.94
Year | PE Ratio | Change |
---|---|---|
2023 | -0.97 | 159.39% |
2022 | -0.38 | -91.34% |
2021 | -4.34 | -87.78% |
2020 | -35.49 | -79.12% |
The current PE Ratio of Pyxis Oncology, Inc. (PYXS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.89
5-year avg
-42.22
10-year avg
-42.22
Pyxis Oncology, Inc.’s PE Ratio is greater than Zura Bio Limited (-5.60), less than eFFECTOR Therapeutics, Inc. (-0.00), less than Altamira Therapeutics Ltd. (-0.03), less than Elevation Oncology, Inc. (-0.85), greater than Mereo BioPharma Group plc (-13.56), greater than PDS Biotechnology Corporation (-1.90), greater than X4 Pharmaceuticals, Inc. (-4.05), greater than Corvus Pharmaceuticals, Inc. (-10.50), greater than Terns Pharmaceuticals, Inc. (-5.12), less than ZyVersa Therapeutics, Inc. (-0.00), less than Ocean Biomedical, Inc. (-0.71), greater than Icosavax, Inc. (-15.78), greater than Inozyme Pharma, Inc. (-1.84), less than HOOKIPA Pharma Inc. (-0.62),
Company | PE Ratio | Market cap |
---|---|---|
-5.60 | $178.25M | |
-0.00 | $941.00 | |
-0.03 | $1.60M | |
-0.85 | $35.67M | |
-13.56 | $575.61M | |
-1.90 | $78.19M | |
-4.05 | $57.64M | |
-10.50 | $575.10M | |
-5.12 | $491.80M | |
-0.00 | $2.65M | |
-0.71 | $24.95M | |
-15.78 | $769.04M | |
-1.84 | $180.51M | |
-0.62 | $20.76M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pyxis Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Pyxis Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Pyxis Oncology, Inc.'s PE Ratio?
How is the PE Ratio calculated for Pyxis Oncology, Inc. (PYXS)?
What is the highest PE Ratio for Pyxis Oncology, Inc. (PYXS)?
What is the 3-year average PE Ratio for Pyxis Oncology, Inc. (PYXS)?
What is the 5-year average PE Ratio for Pyxis Oncology, Inc. (PYXS)?
How does the current PE Ratio for Pyxis Oncology, Inc. (PYXS) compare to its historical average?